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ABSTRACT
Objective: Carry out a bibliographical survey about the use of nanoparticles in the delivery of natural 
products for the treatment of lung cancer.
Methods: A bibliographic review was made using the descriptors “Nanoparticles”, “Biological Prod-
ucts” and “Lung Neoplasms”, through the databases ScienceDirect, PubMed and SciELO, in the period 
from 2009 to 2018.
Results: After analyzing the articles according to the inclusion criteria, we obtained 31 articles, of which 
25.81% refer to natural products in the treatment of lung cancer, 29.03% to nanoparticles in the treatment 
of lung cancer and 45.16 % to nanoparticles as carriers of natural products for the treatment of lung 
cancer.
Conclusion: The use of nanoparticles allows the delivery of natural products, increasing their thera-
peutic properties against lung cancer cells, and decreasing the side effects of these highly toxic agents.
Key words: Nanoparticles; Biological Products; Lung Neoplasms.
RESUMEN
Objetivo: Realizar un estudio bibliográfico sobre el uso de nanopartículas en el transporte de productos 
naturales para el tratamiento del cáncer de pulmón.
Métodos: Se realizó una revisión bibliográfica utilizando los descriptores “Nanoparticles”, “Biological 
Products” y “Lung Neoplasms”, a través de las bases de datos ScienceDirect, PubMed y SciELO, en el 
período comprendido entre 2009 y 2018.
Resultados: Después del análisis de los artículos de acuerdo con los criterios de inclusión, obtuvimos 
31 artículos, de los cuales 25.81% hacían referencia a productos naturales en el tratamiento del cáncer 
de pulmón, el 29.03% a nanopartículas en el tratamiento del cáncer de pulmón y un 45.16 % a nanopar-
tículas como agentes transportadores de productos naturales para el tratamiento del cáncer de pulmón.
Conclusión: El uso de nanopartículas permite el transporte de productos naturales, aumentando sus 
propiedades terapéuticas contra las células de cáncer de pulmón, además de disminuir los efectos secun-
darios de estos agentes altamente tóxicos.
Palabras clave: Nanopartículas; Productos Biológicos; Neoplasias pulmonares.
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INTRODUCTION
Lung cancer accounts for about 2 million new cases of can-
cer worldwide, considered to be one of the most common 
malignancies. Responsible for more than 1.7-1.8 million 
cases of death, it is classified by the Global Burden of Dis-
ease Study (2015) as the main cause of cancer mortality. Ac-
cording to the National Cancer Institute (INCA), estimated 
634,880 new cases of cancer in 2018 in Brazil, of these 31,270 
(14.9%) are referring to new cases of lung cancer(1-3). As in 
other countries, in Brazil, lung cancer is the leading cause 
of cancer death, with a 5-year survival rate, similar to the 
overall rates of 10% to 20%(4).
The therapeutic modalities for lung cancer are surgery, ra-
diotherapy and chemotherapy. Tumors in stages I and II are 
indicated for removal of the tumor, often associated with 
postoperative chemotherapy. Preoperative chemotherapy 
may be indicated at stage III, and is complemented post-
operatively. In more advanced cases, stage IV, the surgical 
approach may be used associated with the use of chemo-
therapy and/or radiotherapy. Brazil is significantly behind 
in the incorporation of systemic therapies and technologies 
for the treatment of lung cancer. Many of the drugs used 
have several side effects compromising the quality of life 
of the patient(5-6).
Natural products represent an important source of bio-
logically active compounds that play an important role in 
the treatment of cancer. Currently, about 60% of the drugs 
found on the market originate from natural products. 
Among these are vinorelbine, vinblastine, vincristine, pa-
clitaxel, cisplatin and etoposide. Despite many findings, 
natural sources are still available in abundance and offer 
better possibilities in the search for substances of therapeu-
tic interest, because despite the arsenal of drugs, several 
solid tumors still do not have suitable treatment, such as 
lung cancer that presents modest responses to all available 
therapeutic regimens(7-8).
It is known that many of the natural products have biophar-
maceutical deficiencies associated with low solubility and 
bioavailability. New therapeutic approaches have emerged 
with the intention of improving these characteristics(9). 
Nanotechnology brings alternatives in the development 
of systems of controlled release of drugs in the treatment 
of various diseases, acting at the target site and enabling 
the potentiation of the therapeutic effects and decrease of 
the side effects of the drugs, being this one of the main 
concerns of the oncological treatment. There are current-
ly several nanosystems that can be classified according to 
the nature of their composition, such as inorganic, lipid or 
polymeric making it possible to reformulate and improve 
existing drugs for the treatment of cancer(10). Therefore, this 
review aimed to carry out a bibliographical survey of the 
use of nanoparticles of natural products for the treatment 
of lung cancer.
METHODS
In this study an integrative review of the literature was car-
ried out, whose purpose is to gather and summarize the 
scientific knowledge already produced related to the topic 
nanoparticles in the use of natural products in the treat-
ment of lung cancer. The preparation of the integrative re-
view was carried out from the following stages: definition 
of the problem and objectives of the research, establishment 
of inclusion criteria and exclusion of publications, search in 
scientific literature, analysis and categorization of studies, 
presentation and discussion of results(11).
In order to carry out the study, the period from 2009 to 2018 
was considered. Data collection was done through a bibli-
ographic survey in the ScienceDirect, PubMed and SciELO 
databases using the descriptors “Nanoparticles”, “Biologi-
cal Products” and “Pulmonary Neoplasms” in its English 
versions.
Inclusion criteria were adopted complete articles published 
in the period established for the research (2009 to 2018), 
which dealt with the use of nanoparticles in improving the 
therapeutic effects of natural products, demonstrating the 
activity of natural products against lung cancer cells and 
which showed the benefits of nanoparticles for the treat-
ment of lung cancer, excluding articles available only in 
summary, articles that although they addressed the thera-
peutic effects of natural products did not refer to lung can-
cer, which demonstrated the benefits of using nanoparticles 
in natural products but did not correlate with lung cancer 
and papers that although they talked about the treatment 
of lung cancer did not refer to the use of natural products.
After reading the selected articles, we continued with the 
analysis and organization of the themes: Natural products 
in the treatment of lung cancer; Nanoparticles in the treat-
ment of lung cancer; Benefits of using nanoparticles as car-
riers of natural products.
RESULTS AND DISCUSSION
A total of 1442 articles were published in the databases pro-
posed in the methodology, in which 1239 were excluded be-
cause they did not fit the established inclusion criteria, 153 
were repeated and 19 were available only in summary, and 
only 31 articles were selected for this review. In this study, 
it was observed that the Journal of Materials Science and 
Engineering: C is what the most publish on this subject, 
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with 19.35% of publications and 2018 was the year with the 
most publications related to the subject analyzed, 32.26% 
of publications, followed by 2015 (16.13% of publications) 
and 2011 (9.68% of publications). Table 1 shows a survey 
of all journals and their respective years of publications on 
the subject.
Table 1 shows a survey of all journals and their respective 
years of publications on the subject. (n) Number of articles 
published and (%) refers to the percentage of the number of 





Acta Biomaterialia 02 6.45 2016, 2015
Biochemical Pharmacology 01 3.22 2010
Biomaterials 01 3.22 2014
Biomedicine & Pharmacotherapy 04 12.90 2018, 2014, 2012
Biosensors and Bioelectronics 01 3.22 2015
Cancer Letters 01 3.22 2011
Colloids and Surfaces B: Biointerfaces 01 3.22 2013
Egyptian Journal of Basic and Applied Sciences 01 3.22 2018
Food and Chemical Toxicology 01 3.22 2011
Human Pathology 01 3.22 2009
International Journal of Biological Macromolecules 03 9.68 2018, 2014
International Journal of Pharmaceutics 02 6.45 2018, 2015
Journal of Controlled Release 02 6.45 2018, 2011
Journal of Thoracic Oncology 01 3.22 2015
Materials Science and Engineering: C 06 19.35 2018, 2017, 2013
Nanomedicine: Nanotechnology, Biology and Medi-
cine
01 3.22 2016
PharmaNutrition 01 3.22 2015
The Lancet Oncology 01 3.22 2012
Total 31 99.92
Source: Research Data
When we evaluated according to the type of publications, 
it was observed that 96.77% of the published articles were 
original articles and 3.22% were articles of revision. Data 
analysis enabled the classification of publications in three 
thematic categories, in which the first refers to the use of 
natural products in the treatment of lung cancer, represent-
ing 25.81% of the publications inserted in this integrative 
review.
Due to the great difficulty of obtaining drugs with great 
therapeutic potentials, the natural products have been ex-
plored in order to supply this need and obtain drugs with 
less toxicity. Paclitaxel and docetaxel are derived from the 
plant Taxus brevifolia and widely used in the treatment of 
several tumors, including non-small cell lung carcinoma(12).
Another plant derivative is Atractylenolide III (ATL-III), 
which is the main bioactive component of the Atractylodes 
rhizome which is related to inhibition of the production of 
tumor necrosis factor alpha (TNF-α) and lipopolysaccha-
ride-induced nitric oxide in macrophages. Kang et al.(13) 
evidence the benefits of ATL-III in the treatment of lung 
cancer by inducing apoptosis in A549 cells of lung carcino-
ma lineage.
Czerwonka et al.(14) tested the aqueous extract of Spirulina, 
which is a dietary supplement derived from algae Arthros-
pira platensis, against non-small cell lung carcinoma A549 
cells, showing in its study anticancer activity and chemo-
preventive properties of Spirulina.
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One of the effective alternatives to increase the cytotoxicity 
of drugs is to associate drugs with different mechanisms of 
action and to be able to destroy a large amount of neoplas-
tic cells. Gorzalczany et al.(15) combined a tyrosine kinase 
inhibitor with autophagy-inducing drugs to combat non-
small cell lung cells expressing epidermal growth factor re-
ceptor (EGFR), showing benefits in the association of these 
agents with the cells of strain A549. Karthik et al.(16) asso-
ciated the drugs romidepsin and bortezomib, noting that 
when associated they potentiate their cytotoxic activity on 
lung cancer cells by inducing synergistically apoptosis in 
lung cancer cells.
Another benefit of the analysis of natural products is the 
possibility of identifying specific markers of a type of can-
cer. Luu et al.(17) proposed the analysis of aspargyl-β-hy-
droxylase (ABH), which are protein products, showing that 
ABH overexpression is probably related to a potential in-
crease in tumor invasion and metastatic spread.
Curcumin is well studied because it has a potential anti-
neoplastic effect, many studies are aimed at improving 
the activity of curcumin in vivo. Imaizumi(18) developed a 
highly bioavailable curcumin called Theracurmin, with a 
therapeutic effect 27 times greater than that of commercial-
ly available curcumin.
The second thematic category deals with nanoparticles in 
the treatment of lung cancer, representing 29.03% of the 
publications of this integrative review.
With the advancement of molecular biology research, it 
was possible to decipher the complexity of the underlying 
biology of lung cancer, offering valuable information, in the 
demonstration of molecularly diverse groups of neoplastic 
processes, leading rapidly to development, clinical evalua-
tion and approval of new targeted drugs specifically for the 
treatment of lung cancer, having as example the potent and 
highly specific tyrosine kinase inhibitors targeting molecu-
lar changes and thereby providing a prolonged control of 
the disease(19-20).
Due to the high toxicity of the chemotherapeutic agents, 
the molecular biology findings allowed to identify specific 
pathophysiological characteristics of some types of tumors, 
leading to the development of therapeutic agents directed 
to the specific markers of each tumor aiming to reduce the 
toxicity due to the systemic of the treatment(21).
As many drugs currently obtained are of vegetable origin, 
they present some biopharmaceutical problems that confer 
low solubility and low bioavailability(18). With the advance-
ment of nanotechnology, it has become possible to develop 
therapeutic formulations based on nanoparticles. Accord-
ing to the European Technological Observatory, in 2006 more 
than 150 pharmaceutical companies were developing na-
noscale therapies in which the idea of controlled drug de-
livery has been shown to improve their therapeutic index, 
increased concentration in specific tissues, organs or cells, 
which led to a decrease in side effects and potentiation of 
the therapeutic effect of the drugs. Because of these advan-
tages, efforts are made to include the chemotherapeutic 
agents, many of which are plant-derived or semisynthet-
ic, in nanosystems to improve cancer therapy(22). Figure 1 
shows the main nanotechnological systems for the treat-
ment of lung cancer.
Figure 1. Main nanosystems tested for the treatment of lung 
cancer
Source: Adapted from Cho et al.(23); Mohanta et al.(24); Pinho & 
Figueiras(25); Zaborski(26); Sharma et al.(27)
Nanocarriers have the potential to modify the properties 
of drugs by increasing their efficacy, stability and solubil-
ity, as well as reducing their toxicity and sustaining their 
release(18,22). The first drug inserted in nanoparticles and ap-
proved by the US Food and Drug Administration (FDA) was 
DOXIL (Figure 2), which is doxorubicin encapsulated in a 
lipid nanoparticle. Research clearly shows that the delivery 
of nanoparticles specifically to cancer cells can increase the 
release of chemotherapeutics into tumors while reducing 
the accumulation of drugs in healthy cells. There are few 
studies that are concerned with studying the use of nano-
particles as carriers of drugs for the treatment of lung can-
cer, targeting only incident cancers such as breast cancer(28). 
Several authors show benefits of using nanoparticles in 
lung cancer, Masood et al.(29) reports in his study that the 
development of poly (3-hydroxybutyrate-co-3-hydroxy-
valerate) based nanoparticles as ellipticine carriers show an 
inhibition of A549 lung cancer cells twice as high as ellip-
ticin alone.
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Figure 2. Liposomes loaded with doxorubicin
Studies also indicate that nanoparticles may enhance the 
activity of drugs widely used in clinical practice. Kumar 
et al.(30) developed vincristine loaded folic acid-chitosan 
nanoparticles (Figure 3) and tested on cancer cells from 
non-small cell lung cancer NCI-H460 showing from the cell 
viability assay a higher cytotoxicity of vincristine in lung 
cancer cells when inserted into the nanoparticles.
Figure 3. Nanoparticle of chitosan conjugated to folic acid loaded 
with vincristine
Rychahou et al.(28) evidence that it is possible to make use 
of polymer nanoparticles as potential drug carriers at the 
pulmonary level for treatment of lung metastases, due to 
the accumulation of polymeric nanoparticles in lung tissue, 
showed a high affinity of polymer nanoparticles for lung 
cells.
Not only focused on improving lung cancer therapy, nano-
technology also allows the detection of lung cancer cells, 
thereby facilitating their diagnosis. Mir et al.(31) used in their 
study, gold nanoparticles for the development of an am-
perometric nanobiosensor for the detection of lung cancer 
cells (A549), showing high affinity of the biosensor for lung 
cancer cells compared to control cells, including prostate 
cancer cells (PC3), normal lung cells (MRC-5) and liver tu-
mor cells (HepG2).
The third thematic category includes articles that consid-
er the benefits of using nanoparticles as carriers of natu-
ral products for the treatment of lung cancer, representing 
45.16% of publications.
The use of the nanoparticles allows to deliver the drugs to 
their target sites, generating a specificity, without causing 
many side effects. Docetaxel is a chemotherapeutic agent 
widely used in the treatment of lung cancer, showed effec-
tiveness in prolonging the life span of many patients, being 
that some patients suffering from allergy, fluid retention, 
leukocyte reduction, alopecia, weakness, among other re-
actions caused by this drug. With the use of nanoparticles 
these effects can be reduced and the efficacy of the treat-
ment can be increased(32). The study by Liang et al.(32) de-
veloped nanoparticles of docetaxel with the polylactic acid 
(PLA) polymer in order to reduce tumor growth and liver 
metastases from small cell lung cancer, obtaining positive 
results both in vitro and in vivo.
In order for the nanoparticle to exhibit selectivity for the 
lung, it is necessary to obtain small nanoparticles, smaller 
than 10 nm, and the composition of the nanoparticle also 
becomes important to obtain stable nanosystems that do 
not present toxicity when administered in the body(33-34). 
The use of chitosan is well explored to obtain several nan-
oparticles due to its high potential in the treatment of lung 
cancer, because it is a natural polysaccharide with non-tox-
ic, biocompatible and biodegradable properties. Samadi et 
al.(34) developed nanofibrous systems with the use of chi-
tosan for the sustained delivery of doxorubicin in the treat-
ment of lung cancer, achieving an effective delivery system 
in inhibiting the proliferation of A549 lineage lung cancer 
cells.
Maya et al.(35) developed chitosan nanoparticles for the 
delivery of docetaxel associated with the monoclonal an-
tibody Cetuximab, as driving agents the expression of the 
EGFR gene for the treatment of non-small cell lung cancer, 
showing that nanosystems can be obtained with the asso-
ciation of drugs used in the clinic, potentiating the effect of 
the drugs due to their targeting on cancer cells.
Another nanotechnology developed as promising for 
the delivery of chemotherapeutic agents is the chitosan 
folate-conjugated carbon nanotubes, developed by Singh et 
al.(36) for the sustained release of docetaxel, showing a high 
cytotoxicity of this system and a low toxicity when com-
pared with docetaxel free. Another important factor is that 
nanocarriers can carry an association of drugs that are com-
patible with each other and that improve the characteristics 
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of the chemotherapeutic agent, is the case of the develop-
ment of vitamin E TGPS nanoparticles with the objective of 
improving the solubilization of paclitaxel, besides helping 
in its mechanism of action, because of the power of such a 
system to retain the drug in the microenvironment, with in-
creased permeability at the tumor target site, thereby lead-
ing to a reduction of the free drug within the bloodstream, 
resulting in improved tolerability and increased efficacy of 
the chemotherapeutic agent(37).
Hydroxyapatite is an inorganic bone component widely 
used in bone tissue reconstruction, and more recent studies 
have found that hydroxyapatite nanoparticles have selec-
tive anticancer activity for lung cancer cells. Ignjatovic et 
al.(38) demonstrate that it is possible to develop hydroxyapa-
tite nanoparticle with chitosan and poly-lactic-co-glycolic 
(PLGA) to make them more selective for the A549 lung can-
cer cell line than for healthy cells. Chen et al.(39) also makes 
use of nanoparticles of hydroxyapatite in the delivery of 
ionizing radiation for the treatment of lung cancer, obtain-
ing positive results and proposing a new alternative for the 
treatment of lung cancer.
New therapeutic approaches were developed from the 
properties of nanosystems, such as the development of 
chitosan micelles with cholesterol for the combined admin-
istration of small fragments of RNA and curcumin with 
cytotoxic activity on lung cancer cells, a promising system 
for the delivery of small fragments of RNA and chemother-
apeutic agent with low solubility for cancer cells(40). Cur-
cumin has promising anticancer properties, however it has 
poor solubility in aqueous medium and low bioavailability, 
Ibrahim et al.(41) encapsulated curcumin in liposomes coat-
ed with lipids of marine origin (Marinosomas) in order to 
develop potential anticancer therapy from low-cost and 
readily available nutraceuticals, showing a favorable sys-
tem of in vitro drug delivery in the fight against lung cancer.
Biological products in addition to presenting cytotoxic ef-
fects to cancer cells may also aid in the development of the 
nanoparticle, being tested as possible ecologically correct 
nanofactors for the development of silver nanoparticles, 
being active against lung cancer cells. Gengan et al.(42) ob-
tained biosynthesized silver nanoparticles using the leaf of 
Albizia adianthifolia, which is an abundant plant on the east 
coast of southern Africa, and presents a range of biological 
and pharmacological activities. Dadashpour et al.(43) also 
managed to obtain silver nanoparticles, using the extract of 
the Matricaria chamomilla plant with positive results against 
the A549 line of lung cells.
CONCLUSIONS
The use of nanoparticles has been widely used as potentia-
tors of the activity of various agents obtained from natural 
products with the aim of improving their pharmaceutical 
properties, decrease their toxicity, and allow the delivery of 
associated agents that minimize the toxicity of drugs wide-
ly used in clinical practice.
Many techniques are being developed to improve the ther-
apy of lung cancer, which is currently the main cause of 
death from cancer. The nanoparticles have a great potential, 
due to their properties that confer selectivity and specificity 
to lung cancer cells, with promising drug delivery systems 
that enable the use of natural products for the treatment of 
lung cancer.
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